|
Dr. Radding brings over 15 years of experience in drug development across a wide range of diseases and therapeutic targets. Prior to Epitome, at Eli Lilly, Dr. Radding spearheaded initiatives for quantitative analysis of signal transduction pathways that incorporated state-of-the-art proteomics platforms, including innovative mass spectrometry approaches. Dr. Radding obtained his Ph.D. in chemistry from Indiana University and completed post-doctoral training in the Department of Internal Medicine at Yale University School of Medicine. | 